Assembly Biosciences (ASMB) closed at $22.50 on November 17, 2026, up 5.7% from the previous close, on volume of 311,179 shares (30-day average 245,191).
Data as of November 17, 2026.
TipRanks (Tue, 17-Nov 12:30 PM ET)
Guggenheim Remains a Buy on Assembly Biosciences (ASMB)
TipRanks (Mon, 16-Nov 8:17 AM ET)
Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
Globe Newswire (Thu, 12-Nov 4:00 PM ET)
Assembly Biosciences to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Nov 4:00 PM ET)
Globe Newswire (Thu, 29-Oct 4:00 PM ET)
Globe Newswire (Mon, 5-Oct 10:00 AM ET)
Globe Newswire (Thu, 10-Sep 4:15 PM ET)
Globe Newswire (Tue, 8-Sep 4:00 PM ET)
Market Chameleon (Fri, 20-Mar 5:59 AM ET)
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Assembly Biosciences trades on the NASDAQ stock market under the symbol ASMB.
As of November 18, 2026, ASMB stock price declined to $22.48 with 307,511 million shares trading.
ASMB has a beta of 0.96, meaning it tends to be less sensitive to market movements. ASMB has a correlation of 0.05 to the broad based SPY ETF.
ASMB has a market cap of $460.33 million. This is considered a Small Cap stock.
Last quarter Assembly Biosciences reported $3 million in Revenue and -$.93 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.45.
In the last 3 years, ASMB traded as high as $39.71 and as low as $7.69.
The top ETF exchange traded funds that ASMB belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
ASMB has underperformed the market in the last year with a return of -38.1%, while the SPY ETF gained +10.9%. In the last 3 month period, ASMB fell short of the market, returning -25.1%, while SPY returned -5.2%. However, in the most recent 2 weeks ASMB has outperformed the stock market by returning +12.9%, while SPY returned -3.2%.
ASMB support price is $21.64 and resistance is $23.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASMB shares will trade within this expected range on the day.